Showing 1121-1130 of 10595 results for "".
Sensus Healthcare: What's Next
https://practicaldermatology.com/topics/skin-cancer-photoprotection/sensus-healthcare-whats-next/19947/Along with other healthcare companies, Sensus faced challenges in 2020 as the COVID-19 pandemic emerged. But CEO Joe Sardano says the company is poised for success in 2021 and beyond. He discusses efforts to optimize physician reimbursement and strategies to expand access for patients.Sensus Healthcare: What's New
https://practicaldermatology.com/topics/skin-cancer-photoprotection/sensus-healthcare-whats-new/19946/Adding to its flagship SRT-100 device for superficial radiation therapy, Sensus has launched the Sculptura® Radiotherapy Oncology System and is poised to bring new aesthetic devices to market. Sensus CEO Joe Sardano says that as it grows, the company remains focused on relationships with its clientsScientifically Speaking: New Directions in Acne Management, Part 1
https://practicaldermatology.com/videos/scientifically-speaking/scientifically-speaking-new-directions-in-acne-management-part-1/19939/The recognition that inflammation is at the heart of acne has led to changes in management approaches and better understanding of how treatments work. In the first of a 2-part series, host Joel L. Cohen, MD talks to Diane Berson, MD; Linda Stein Gold, MD; and Emil Tanghetti, MD about acne approachesAlmost There: Toward Systemic Therapy for AD in Children
https://practicaldermatology.com/topics/atopic-dermatitis/almost-there-toward-systemic-therapy-for-ad-in-children/19934/With the approval of the first biologic for management of atopic dermatitis, a new era is underway, says Amy Paller, MD. She addresses the role of dupilumab in practice and provides a look ahead at other agents in the pipeline for adolescent and pediatric patients.What's the last show you binge-watched?
https://practicaldermatology.com/topics/general-topics/whats-the-last-show-you-binge-watched/19875/Nazanin Saedi, MD tells us which show made her laugh and how she can't wait for the next season!RF Technologies: What should you know?
https://practicaldermatology.com/videos/scientifically-speaking/rf-technologies-what-should-you-know/19848/With so many radiofrequency devices now on the market and new ones in development, aesthetic specialists need to know how to select the proper tool for each patient need. E. Victor Ross, MD and Erez Dayan, MD join host Joel L. Cohen, MD to go beyond the marketing jargon to assess the science and cliPsO Treatment Guidelines: The Role of Systemic Medications
https://practicaldermatology.com/topics/psoriasis/pso-treatment-guidelines-the-role-of-systemic-medications/19649/Biologics and new JAK inhibitors play an important role in managing psoriasis. Neal Bhatia, MD offers his thoughts on when and why these treatments should be considered.Grub Flubs: The Foods That Can Hurt the Skin
https://practicaldermatology.com/topics/general-topics/grub-flubs-the-foods-that-can-hurt-the-skin/19539/There's no doubt diet affects skin, says Rajani Katta, MD. She explains which foods can benefit the skin and which can have a detrimental effect. Hint: Sugar isn't so sweet.UV Safety Goes Viral, Salon Exposures Exposed
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-uv-safety-goes-viral-salon-exposures-exposed/18439/The Skin Checker viral video from La Roche Posay coincides with the launch of La Roche Posay's new Anthelios Dermo-KIDS Sunscreen SPF 60. The company has also reported data showing the benefits of its wearable My UV Patch sensor and associated kid-friendly mobile app. Neutrogena's MimicMommy MOVEmenRhatigan to Merz, MOC Dissatisfaction, Syneron-Candela Sale
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-rhatigan-to-merz-moc-dissatisfaction-syneron-candela-sale/18485/Industry veteran Bob Rhatigan is the new President and Chief Executive Officer of Merz North America. Patrick Urban is new Chief Commercial Officer. In a transaction valued at approximately $397 million, an affiliate of funds advised by Apax Partners will acquire all of the outstanding shares of Sy